Presence of Kynurenic Acid in the Mammalian Brain
- F. Moroni, P. Russi, G. Lombardi, M. Beni, V. Carlá
- Biology, ChemistryJournal of Neurochemistry
- 1 July 1988
Kynurenic acid, a tryptophan metabolite able to antagonize the actions of the excitatory amino acids, has been identified and measured for the first time in the brain of mice, rats, guinea pigs, and humans by using an HPLC method, suggesting that its turnover rate is relatively fast.
High mobility group box 1 protein is released by neural cells upon different stresses and worsens ischemic neurodegeneration in vitro and in vivo
- G. Faraco, S. Fossati, A. Chiarugi
- BiologyJournal of Neurochemistry
- 1 October 2007
Investigation of the expression levels and relocation dynamics of HMGB1 in neural cells, as well as its neuropathological potential, point to the protein as a mediator of post‐ischemic brain damage.
Pharmacological characterization of 1-aminoindan-1,5-dicarboxylic acid, a potent mGluR1 antagonist.
- F. Moroni, G. Lombardi, R. Pellicciari
- Biology, ChemistryJournal of Pharmacology and Experimental…
- 1 May 1997
The pharmacological profile of 1-aminoindan-1,5-dicarboxylic acid, a rigid (carboxyphenyl)glycine derivative acting on metabotropic glutamate receptors (mGluRs) is examined to suggest that AIDA is a potent, selective and competitive mGluR1 a antagonist.
Pharmacological Inhibition of Histone Deacetylases by Suberoylanilide Hydroxamic Acid Specifically Alters Gene Expression and Reduces Ischemic Injury in the Mouse Brain
- G. Faraco, Tristano Pancani, A. Chiarugi
- BiologyMolecular Pharmacology
- 1 December 2006
It is demonstrated that pharmacological inhibition ofHDACs promotes expression of neuroprotective proteins within the ischemic brain and underscores the therapeutic potential of molecules inhibiting HDACs for stroke therapy.
Tryptophan metabolism and brain function: focus on kynurenine and other indole metabolites.
- F. Moroni
- Biology, ChemistryEuropean Journal of Pharmacology
- 30 June 1999
1-Aminoindan-1,5-dicarboxylic acid: a novel antagonist at phospholipase C-linked metabotropic glutamate receptors.
- R. Pellicciari, R. Luneia, C. Thomsen
- ChemistryJournal of Medicinal Chemistry
- 15 September 1995
G-protein coupled receptor 35 (GPR35) activation and inflammatory pain: Studies on the antinociceptive effects of kynurenic acid and zaprinast
- C. Cosi, G. Mannaioni, F. Moroni
- BiologyNeuropharmacology
- 1 June 2011
GPR35 Activation Reduces Ca2+ Transients and Contributes to the Kynurenic Acid-Dependent Reduction of Synaptic Activity at CA3-CA1 Synapses
- R. Berlinguer-Palmini, A. Masi, G. Mannaioni
- BiologyPLoS ONE
- 29 November 2013
GPR35 is expressed in cultured astrocytes and its activation modulates cAMP production and [Ca2+]i and may contribute to KYNA effects on the previously reported decrease of brain extracellular glutamate levels and reduction of excitatory transmission.
The Release and Neosynthesis of Glutamic Acid Are Increased in Experimental Models of Hepatic Encephalopathy
- F. Moroni, G. Lombardi, G. Moneti, C. Cortesini
- Biology, ChemistryJournal of Neurochemistry
- 1 March 1983
Results indicate that ammonium ions increase the release and the formation of glutamic acid in the brain and may be one of the mechanisms of ammonia toxicity in vivo.
Presynaptic kynurenate‐sensitive receptors inhibit glutamate release
- R. Carpenedo, A. Pittaluga, F. Moroni
- Biology, ChemistryEuropean Journal of Neuroscience
- 1 June 2001
The data show that kynurenate‐induced inhibition of glutamate release is not mediated by glutamate receptors, and Nicotinic acetylcholine receptors may contribute to the inhibitory effects of kynurenic acid found in microdialysis studies, but not in those found in isolated synaptosomes.
...
...